#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15106	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2444	758.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1878	1878	T	959	T,C,A	956,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	15106	16S	1529	1529	99.93	16S.l15.c17.ctg.1	2444	758.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1612	1612	C	960	C,T	958,2	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26894	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3987	839.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1891	1891	A	1118	A,T,G,C	1115,1,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26894	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3987	839.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2525	2525	C	952	C	950	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26894	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3987	839.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2599	2599	A	911	A,G,C	909,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26894	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3987	839.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3151	3151	C	937	C,T,A,G	932,2,2,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	27	2350	folP	852	852	99.88	folP.l15.c4.ctg.1	2051	142.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5256	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4070	161.0	0	.	p	.	0	D515N	NONSYN	1543	1545	GAC	2242	2244	AAC	217;217;214	A,G;A;C,A	216,1;217;213,1	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5256	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4070	161.0	1	SNP	p	S91F	0	.	.	271	273	TCC	970	972	TCC	171;170;168	T;C,T;C	171;169,1;167	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5256	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4070	161.0	1	SNP	p	D95N	0	.	.	283	285	GAC	982	984	GAC	163;164;166	G;A,T,G;C	163;162,1,1;166	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5256	gyrA	2751	2751	99.82	gyrA.l15.c4.ctg.1	4070	161.0	1	SNP	p	D95G	0	.	.	283	285	GAC	982	984	GAC	163;164;166	G;A,T,G;C	163;162,1,1;166	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1866	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1732	133.9	0	.	p	.	0	A39T	NONSYN	115	117	GCC	616	618	ACC	201;201;199	A;C,T;C,A	201;200,1;198,1	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1866	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1732	133.9	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	814	816	CAC	251;250;249	C,G;A;C	250,1;250;249	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1866	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1732	133.9	0	.	p	.	0	E117K	NONSYN	349	351	GAA	850	852	AAA	220;220;218	A;A,C;A,G	220;219,1;215,3	.	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	539	1866	mtrR	633	633	99.21	mtrR.l6.c4.ctg.1	1732	133.9	1	SNP	p	G45D	0	.	.	133	135	GGC	634	636	GGC	215;215;217	G;G;C,G	215;215;216,1	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1156	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c17.ctg.1	1512	95.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	0	.	p	.	0	V384I	NONSYN	1150	1152	GTC	1707	1709	ATC	227;230;228	A,G;T;C	226,1;230;228	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1860	1862	GCA	246;249;249	G;C;A,T,C	246;249;247,1,1	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2343	2345	ATT	224;225;224	A,G,C;T,C;T	222,1,1;224,1;224	.	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	1	SNP	p	D86N	0	.	.	256	258	GAC	813	815	GAC	235;233;232	G;A;C	235;232;231	parC.WHO_F_01444:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	1	SNP	p	S87I	0	.	.	259	261	AGT	816	818	AGT	234;234;235	A,T;G;T	231,2;233;234	parC.WHO_F_01444:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	1	SNP	p	S87W	0	.	.	259	261	AGT	816	818	AGT	234;234;235	A,T;G;T	231,2;233;234	parC.WHO_F_01444:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	1	SNP	p	S87R	0	.	.	259	261	AGT	816	818	AGT	234;234;235	A,T;G;T	231,2;233;234	parC.WHO_F_01444:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_F_01444	parC.WHO_F_01444	1	1	539	5104	parC	2304	2304	99.7	parC.l15.c4.ctg.1	3453	184.2	1	SNP	p	S88P	0	.	.	262	264	TCC	819	821	TCC	234;233;231	T,G;C,T,G;C	232,1;230,1,1;230	parC.WHO_F_01444:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4416	parE	1986	1986	99.95	parE.l6.c4.ctg.1	3243	169.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1886	1888	GGC	240;240;240	G;G,A,C;C	240;236,2,1;240	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	A311V	0	.	.	931	933	GCA	1485	1487	GCA	229;231;234	G,T;C,A;A	228,1;230,1;234	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	I312M	0	.	.	934	936	ATC	1488	1490	ATC	231;232;230	A;T;C,G	231;232;229,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	V316T	0	.	.	946	948	GTG	1500	1502	GTG	238;238;238	G,T;T;G,C	237,1;238;237,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	V316P	0	.	.	946	948	GTG	1500	1502	GTG	238;238;238	G,T;T;G,C	237,1;238;237,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2004	2006	ACC	241;241;241	A;C,T,A;C	241;239,1,1;241	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2058	2060	GCG	266;266;264	G;C;G	266;266;264	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2058	2060	GCG	266;266;264	G;C;G	266;266;264	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	G543S	0	.	.	1627	1629	GGT	2181	2183	GGT	254;252;254	G,A,T;G,T;T,C	252,1,1;251,1;253,1	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2190	2192	GGC	260;261;261	G;G;C,A	259;260;260,1	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4366	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2796	194.5	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2208	2210	CCG	269;269;268	C,G;C,T;G	268,1;268,1;267	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5808	ponA	2397	2397	99.96	ponA.l6.c4.ctg.1	3654	198.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2556	porA	1146	1146	99.65	porA.l15.c17.ctg.1	2259	141.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	766	766	C	201	C	201	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	V135M	NONSYN	403	405	GTG	1003	1005	ATG	253;256;259	A,G;T;G,A	252,1;256;258,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	1027	1029	CAA	263;265;262	C,A;A;A,C	262,1;265;261,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	E212D	NONSYN	634	636	GAA	1234	1236	GAT	246;247;243	G;A,G,C,T;T	246;244,1,1,1;243	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	H213D	NONSYN	637	639	CAT	1237	1239	GAT	245;243;239	G;A,T;T	245;242,1;239	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	I218M	NONSYN	652	654	ATC	1252	1254	ATG	247;247;243	A;T;G	247;245;242	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	R257K	NONSYN	769	771	AGG	1369	1371	AAG	237;237;239	A,G;A,T;G,A	236,1;236,1;238,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	0	.	p	.	0	S295N	NONSYN	883	885	AGT	1483	1485	AAT	222;222;220	A,C;A;T,G	221,1;222;219,1	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	3006	porB1b	1047	1047	99.04	porB1b.l6.c4.ctg.1	2091	178.6	1	SNP	p	G120K	0	.	.	358	360	GGC	958	960	GGC	223;223;223	G;G;C	223;223;223	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10226	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5375	237.0	0	.	p	.	0	T6I	NONSYN	16	18	ACC	527	529	ATC	256;259;261	A;T,A;C,T	256;258,1;260,1	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10226	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	5375	237.0	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2168	2170	CAT	264;262;261	C;A,C;T	264;261,1;261	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1442	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1555	115.5	1	SNP	p	V57M	0	.	.	169	171	GTG	760	762	GTG	254;252;248	G;T;G	254;252;248	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	16988	tetM	1920	1920	100.0	tetM.l15.c17.ctg.1	3090	684.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
